K 9
Alternative Names: K-9; kamuvudine-9Latest Information Update: 28 Sep 2024
At a glance
- Originator Inflammasome Therapeutics
- Class Eye disorder therapies
- Mechanism of Action NLRC4 protein inhibitors; NLRP3 protein inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Graves ophthalmopathy
- Preclinical Autoimmune disorders; Neurodegenerative disorders
Most Recent Events
- 17 Sep 2024 Preclinical trials in Autoimmune disorders in USA (PO), prior to September 2024
- 17 Sep 2024 Preclinical trials in Neurodegenerative disorders in USA (PO), prior to September 2024
- 10 Sep 2024 Inflammasome Therapeutics completes enrolment in its phase I trial for Graves ophthalmology in USA